Compared to the anti-EGFR MMAE-conjugated cetuximab, the bispecific ADC displayed reduced in vitro binding activity and reduced cellular cytotoxicity when applied to healthy cells (e.g., HepG2 and human keratinocytes), while demonstrating high potency in tumor cells that express both targets (EGFR and c-Met) [224]. Here, EGFR is linked to neoplasm.